Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

BACKGROUND: The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count > 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB therapy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tweed, Conor D., Crook, Angela M., Dawson, Rodney, Diacon, Andreas H., McHugh, Timothy D., Mendel, Carl M., Meredith, Sarah K., Mohapi, Lerato, Murphy, Michael E., Nunn, Andrew J., Phillips, Patrick P. J., Singh, Kasha P., Spigelman, Melvin, Gillespie, Stephen H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694514/
https://www.ncbi.nlm.nih.gov/pubmed/31412895
http://dx.doi.org/10.1186/s12890-019-0907-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694514/
https://www.ncbi.nlm.nih.gov/pubmed/31412895
http://dx.doi.org/10.1186/s12890-019-0907-6

Ejemplares similares